(NP -LCB-/-LRB- (NP Regulation/NN) (PP of/IN (NP (NP intracellular/JJ cholesterol/NN synthesis/NN) (PP in/IN (NP hypercholesterolemia/NN)))) (PP by/IN (NP glucocorticoids/NNS)) -RCB-/-RRB-)
(S (NP-SBJ-1 (NP The/DT rate/NN) (PP of/IN (NP (NP endogenous/JJ cholesterol/NN synthesis/NN) (PP in/IN (NP (NP-COOD (NP blood/NN lymphocytes/NNS) and/CC (NP skin/NN fibroblasts/NNS)) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP type/NN IIa/NN hyperlipidemia/NN))))))))) (VP was/VBD (VP found/VBN (S (NP-SBJ-2 *-1/-NONE-) (VP to/TO (VP be/VB (VP increased/VBN (NP *-2/-NONE-) (PP in/IN comparison/NN with/IN (NP healthy/JJ donors/NNS)))))))) ./.)
(S (NP-SBJ (NP The/DT cells/NNS) (PP of/IN (NP hyperlipidemic/JJ patients/NNS))) (VP had/VBD (NP (NP lowered/JJ levels/NNS) (PP of/IN (NP glucocorticoid/NN receptors/NNS))) (PP concomitantly/RB with/IN (NP (NP a/DT partial/JJ loss/NN) (PP of/IN (NP (NP their/PRP$ sensitivity/NN) (PP to/TO (NP glucocorticoids/NNS))))))) ./.)
(S (PP In/IN (NP (NP fibroblasts/NNS) (PP from/IN (NP (NP patients/NNS) (PP with/IN (NP (NP hereditary/JJ hypercholesteremia/NN) (PP of/IN (NP homozygous/JJ type/NN)))))))) (NP-SBJ (NP the/DT number/NN) (PP of/IN (NP glucocorticoid/NN receptors/NNS))) (VP did/VBD not/RB (VP exceed/VB (NP (NP 10/CD %/NN) (PP of/IN (NP (NP their/PRP$ content/NN) (PP in/IN (NP normal/JJ cells/NNS))))))) ./.)
(S (NP-SBJ-3 (NP The/DT decrease/NN) (PP of/IN (NP (NP the/DT number/NN) (PP of/IN (NP (NP glucocorticoid/NN receptors/NNS) (PP in/IN (NP (NP patients/NNS) (PP with/IN (NP type/NN IIa/NN hyperlipidemia/NN))))))))) (VP seems/VBZ (S (NP-SBJ *-3/-NONE-) (VP to/TO (VP be/VB (NP-PRD (NP a/DT compensatory/JJ response/NN) (PP of/IN (NP (NP cells/NNS) (VP culminating/VBG (PP in/IN (NP (NP activation/NN) (PP of/IN (NP endogenous/JJ cholesterol/NN synthesis/NN)))))))))))) ./.)
